NASDAQ:APTX Aptinyx (APTX) Stock Forecast, Price & News $0.07 0.00 (0.00%) (As of 06/1/2023 ET) Add Compare Share Share Today's Range$0.07▼$0.0750-Day Range$0.06▼$0.1552-Week Range$0.05▼$0.74Volume400,759 shsAverage Volume2.95 million shsMarket Capitalization$4.81 millionP/E RatioN/ADividend YieldN/APrice Target$1.38 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Aptinyx MarketRank™ ForecastAnalyst RatingHold2.13 Rating ScoreUpside/Downside1,836.6% Upside$1.38 Price TargetShort InterestHealthy2.92% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.40) to ($0.10) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.26 out of 5 stars 3.1 Analyst's Opinion Consensus RatingAptinyx has received a consensus rating of Hold. The company's average rating score is 2.13, and is based on 1 buy rating, 7 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $1.38, Aptinyx has a forecasted upside of 1,836.6% from its current price of $0.07.Amount of Analyst CoverageAptinyx has only been the subject of 1 research reports in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted2.92% of the float of Aptinyx has been sold short.Short Interest Ratio / Days to CoverAptinyx has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Aptinyx has recently decreased by 41.70%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldAptinyx does not currently pay a dividend.Dividend GrowthAptinyx does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for APTX. Previous Next 2.8 News and Social Media Coverage News SentimentAptinyx has a news sentiment score of 1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.47 average news sentiment score of Medical companies.Search Interest8 people have searched for APTX on MarketBeat in the last 30 days. This is an increase of 60% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Aptinyx insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 9.88% of the stock of Aptinyx is held by insiders.Percentage Held by Institutions45.93% of the stock of Aptinyx is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Aptinyx are expected to grow in the coming year, from ($0.40) to ($0.10) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Aptinyx is -0.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Aptinyx is -0.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAptinyx has a P/B Ratio of 0.26. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Aptinyx (NASDAQ:APTX) StockAptinyx Inc. is a clinical stage biopharmaceutical company, which engages in discovery, development, and commercialization of transformative therapies for disorders of the brain and nervous system. Its product includes NYX-2925, NYX-783, NYX-458, and the AGN-241751 program. The company was founded by Norbert G. Riedel and Joseph R. Moskal in June 2015 and is headquartered in Evanston, IL.Read More Receive APTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Aptinyx and its competitors with MarketBeat's FREE daily newsletter. Email Address APTX Stock News HeadlinesMay 18, 2023 | americanbankingnews.comAnalysts Set Aptinyx Inc. (NASDAQ:APTX) Price Target at $1.50May 9, 2023 | americanbankingnews.comAptinyx (APTX) to Release Quarterly Earnings on WednesdayJune 1, 2023 | Edge On The Street (Ad)The $193 Billion US-China War You Don't Know AboutThey're fighting for control of lithium – a key ingredient in EVs and clean energy technology. It's arguably the most important commodity of the 21st century. China owns 80% of global supply. But the US plans to grab a massive slice of the lithium market, which is forecasted to quadruple to $193 billion by 2028, according to Fortune Business Insights.May 9, 2023 | americanbankingnews.comAptinyx (APTX) Set to Announce Earnings on WednesdayMay 2, 2023 | americanbankingnews.comAptinyx Inc. (NASDAQ:APTX) Short Interest UpdateApril 23, 2023 | americanbankingnews.comBrokerages Set Aptinyx Inc. (NASDAQ:APTX) PT at $1.50April 15, 2023 | americanbankingnews.comShort Interest in Aptinyx Inc. (NASDAQ:APTX) Increases By 681.9%April 4, 2023 | americanbankingnews.comBrokers Issue Forecasts for Aptinyx Inc.'s Q1 2024 Earnings (NASDAQ:APTX)June 1, 2023 | Edge On The Street (Ad)The $193 Billion US-China War You Don't Know AboutThey're fighting for control of lithium – a key ingredient in EVs and clean energy technology. It's arguably the most important commodity of the 21st century. China owns 80% of global supply. But the US plans to grab a massive slice of the lithium market, which is forecasted to quadruple to $193 billion by 2028, according to Fortune Business Insights.March 31, 2023 | americanbankingnews.comAptinyx Inc. (NASDAQ:APTX) Short Interest Up 48.6% in MarchMarch 31, 2023 | americanbankingnews.comAptinyx Inc. (NASDAQ:APTX) Receives Average Rating of "Hold" from AnalystsMarch 30, 2023 | finance.yahoo.comHere's Why Aptinyx Inc. (APTX) Is a Great 'Buy the Bottom' Stock NowFebruary 27, 2023 | finance.yahoo.comAptinyx Reports Results from Phase 2 Study of NYX-458 in Cognitive Impairment Associated with Parkinson's Disease and Dementia with Lewy Bodies and Provides Pipeline and Corporate UpdateJanuary 31, 2023 | finance.yahoo.comAptinyx to Present at the SVB Securities Global Biopharma ConferenceJanuary 16, 2023 | ca.finance.yahoo.comAptinyx Inc. (APTX) Stock Historical Prices & Data - Yahoo FinanceJanuary 5, 2023 | fool.comAptinyx (NASDAQ: APTX)December 30, 2022 | insidermonkey.comAptinyx Inc. (NASDAQ:APTX) Q3 2022 Earnings Call TranscriptDecember 12, 2022 | markets.businessinsider.comH.C. Wainwright Keeps Their Buy Rating on Aptinyx (APTX)November 8, 2022 | finance.yahoo.comAptinyx Reports Third Quarter 2022 Financial Results and Recent HighlightsOctober 30, 2022 | fool.comAptinyx Inc. (NASDAQ: APTX)October 18, 2022 | finance.yahoo.comAptinyx to Report Third Quarter 2022 Financial Results on Tuesday, November 8, 2022October 2, 2022 | reuters.comAPTX.OQ - Aptinyx Inc | Stock Price & Latest News | ReutersSeptember 24, 2022 | finance.yahoo.comAptinyx Inc. (APTX)September 12, 2022 | nasdaq.comHopeful week for insiders who might be regretting buying US$567k of Aptinyx Inc. (NASDAQ:APTX) stock earlier this year - NasdaqAugust 26, 2022 | marketscreener.comHC Wainwright Adjusts Price Target on Aptinyx to $1 From $2, Reiterates Buy Rating - Marketscreener.comAugust 25, 2022 | businesswire.comAptinyx Completes Enrollment in Phase 2 Study of NYX-458 in Cognitive Impairment Associated with Parkinson's Disease and Dementia with Lewy Bodies - Business WireAugust 25, 2022 | finance.yahoo.comAptinyx Completes Enrollment in Phase 2 Study of NYX-458 in Cognitive Impairment Associated with Parkinson’s Disease and Dementia with Lewy BodiesSee More Headlines APTX Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart APTX Company Calendar Last Earnings3/30/2023Today6/01/2023Next Earnings (Estimated)8/03/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:APTX CUSIPN/A CIK1674365 Webwww.aptinyx.com Phone(847) 871-0377FaxN/AEmployees40Year FoundedN/APrice Target and Rating Average Stock Price Forecast$1.38 High Stock Price Forecast$2.00 Low Stock Price Forecast$0.50 Forecasted Upside/Downside+1,836.6%Consensus RatingHold Rating Score (0-4)2.13 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)($0.98) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-64,850,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-157.89% Return on Assets-93.36% Debt Debt-to-Equity Ratio1.12 Current Ratio5.12 Quick Ratio5.12 Sales & Book Value Annual Sales$1 million Price / Sales4.81 Cash FlowN/A Price / Cash FlowN/A Book Value$0.27 per share Price / Book0.26Miscellaneous Outstanding Shares67,720,000Free Float61,026,000Market Cap$4.81 million OptionableNot Optionable Beta1.33 Key ExecutivesAndrew KiddCEO, Chief Financial & Accounting OfficerCraig R. JalbertPresident, Secretary, Treasurer & DirectorKathryn KingSenior Vice President-Clinical & CMC OperationsPatrick FlavinHead-Media & Investor RelationsTim NoffkeChief of Staff & Vice President-Program ManagementKey Competitors180 Life SciencesNASDAQ:ATNFArtelo BiosciencesNASDAQ:ARTLXenetic BiosciencesNASDAQ:XBIOQualigen TherapeuticsNASDAQ:QLGNOncorusNASDAQ:ONCRView All CompetitorsInstitutional OwnershipRenaissance Technologies LLCSold 166,000 shares on 5/12/2023Ownership: 0.668%Acadian Asset Management LLCBought 252,549 shares on 5/11/2023Ownership: 0.560%Virtu Financial LLCBought 280,430 shares on 5/1/2023Ownership: 0.414%Simplex Trading LLCBought 100 shares on 4/27/2023Ownership: 0.000%View All Institutional Transactions APTX Stock - Frequently Asked Questions Should I buy or sell Aptinyx stock right now? 8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Aptinyx in the last twelve months. There are currently 7 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" APTX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in APTX, but not buy additional shares or sell existing shares. View APTX analyst ratings or view top-rated stocks. What is Aptinyx's stock price forecast for 2023? 8 Wall Street research analysts have issued 12-month target prices for Aptinyx's shares. Their APTX share price forecasts range from $0.50 to $2.00. On average, they expect the company's share price to reach $1.38 in the next twelve months. This suggests a possible upside of 1,836.6% from the stock's current price. View analysts price targets for APTX or view top-rated stocks among Wall Street analysts. How have APTX shares performed in 2023? Aptinyx's stock was trading at $0.2853 at the beginning of the year. Since then, APTX stock has decreased by 75.1% and is now trading at $0.0710. View the best growth stocks for 2023 here. Are investors shorting Aptinyx? Aptinyx saw a decrease in short interest during the month of May. As of May 15th, there was short interest totaling 1,300,000 shares, a decrease of 41.7% from the April 30th total of 2,230,000 shares. Based on an average daily trading volume, of 4,450,000 shares, the short-interest ratio is currently 0.3 days. Approximately 2.9% of the company's stock are sold short. View Aptinyx's Short Interest. When is Aptinyx's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 3rd 2023. View our APTX earnings forecast. How were Aptinyx's earnings last quarter? Aptinyx Inc. (NASDAQ:APTX) announced its earnings results on Thursday, March, 30th. The company reported ($0.18) EPS for the quarter, beating analysts' consensus estimates of ($0.19) by $0.01. What other stocks do shareholders of Aptinyx own? Based on aggregate information from My MarketBeat watchlists, some companies that other Aptinyx investors own include Onconova Therapeutics (ONTX), VBI Vaccines (VBIV), Sorrento Therapeutics (SRNE), OPKO Health (OPK), Kadmon (KDMN), Matinas BioPharma (MTNB), Cidara Therapeutics (CDTX), ADMA Biologics (ADMA), DURECT (DRRX) and Catalyst Pharmaceuticals (CPRX). When did Aptinyx IPO? (APTX) raised $77 million in an initial public offering on Thursday, June 21st 2018. The company issued 5,300,000 shares at a price of $14.00-$15.00 per share. J.P. Morgan, Cowen, Leerink Partners and BMO Capital Markets acted as the underwriters for the IPO. What is Aptinyx's stock symbol? Aptinyx trades on the NASDAQ under the ticker symbol "APTX." Who are Aptinyx's major shareholders? Aptinyx's stock is owned by many different institutional and retail investors. Top institutional shareholders include Renaissance Technologies LLC (0.67%), Acadian Asset Management LLC (0.56%), Virtu Financial LLC (0.41%) and Simplex Trading LLC (0.00%). Insiders that own company stock include Ashish Khanna, Bain Capital Life Sciences Inv, Joan W Miller, Norbert G Riedel and Robert J Hombach. View institutional ownership trends. How do I buy shares of Aptinyx? Shares of APTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Aptinyx's stock price today? One share of APTX stock can currently be purchased for approximately $0.07. How much money does Aptinyx make? Aptinyx (NASDAQ:APTX) has a market capitalization of $4.81 million and generates $1 million in revenue each year. The company earns $-64,850,000.00 in net income (profit) each year or ($0.98) on an earnings per share basis. How can I contact Aptinyx? Aptinyx's mailing address is 909 DAVIS STREET SUITE 600, EVANSTON IL, 60201. The official website for the company is www.aptinyx.com. The company can be reached via phone at (847) 871-0377 or via email at investors@aptinyx.com. This page (NASDAQ:APTX) was last updated on 6/1/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aptinyx Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.